Clinical trials: Ischemic Lesions
Periprocedural Myonecrosis
Intracoronary Electrocardiogram (ECG) and Myonecrosis After Bifurcation Stenting
The coronary bifurcation lesions pose a therapeutic problem with high rates of periprocedural complications, higher rates of in-stent restenosis and stent thrombosis.
- Trial name
- COSIBRIA&CO (NCT01268228)
- Where
- 3 sites in Bulgaria, Poland
- Volunteers
- 131 people, healthy volunteers welcome
- Sponsor
- University National Heart Hospital
Coronary Heart Disease
The Study of Active Transfer of Plaque Technique for Non-Left Main Coronary Bifurcation Lesions
A Prospective Multi-center Randomized Trial Assessing the Efficacy and Safety of Active Transfer of Plaque vs. Provisional T Stenting for the Treatment of Non-Left-Main Coronary Bifurcation Lesions.
- Trial name
- NCT02768116
- Testing
- Sirolimus Drug-eluting Stent via Active Transfer of Plaque, Sirolimus Drug-eluting Stent implantation via Provisional T Stenting
- Volunteers
- 316 people
- Sponsor
- Beijing Anzhen Hospital
Safety Issues, Efficacy, Self
The Lower Silesia Shockwave Registry
Lower Silesia Shockwave Registry (LSSR), is a observational registry collecting all consecutive cases of percutaneous coronary intervention (PCI) performed with the support of shockwave intravascular lithotripsy in two…
- Trial name
- LSSR (NCT05916898)
- Testing
- PCI with support of Shockwave Intravascular Lithotripsy
- Where
- 2 sites in Poland
- Volunteers
- 400 people
- Sponsor
- Miedziowe Centrum Zdrowia SA
Coronary Disease
Safety and Efficacy Study of the DANUBIO Paclitaxel Eluting Balloon in Side Branches of de Novo Bifurcation Lesions (DEBSIDE)
The purpose of this study is to assess the safety and efficacy of the Danubio Paclitaxel Eluting Balloon for the treatment of side branches of de novo bifurcation lesions in native coronary arteries.
- Trial name
- DEBSIDE (NCT01485081)
- Testing
- Danubio paclitaxel-eluting balloon
- Where
- 7 sites in France
- Volunteers
- 52 people
- Sponsor
- MINVASYS
Coronary Artery Disease, Coronary Atherosclerosis
Study Comparing the CYPHER® ELITE™ to the CYPHER® Bx VELOCITY® Sirolimus-Eluting Stent Systems
The objective of this study is to show similar (non-inferior) safety and effectiveness between CYPHER® ELITE™ and CYPHER® Bx VELOCITY® Sirolimus-Eluting Stent Systems in a prospective, multi-center, randomized clinical study for…
- Trial name
- ELITE (NCT00715884)
- Testing
- CYPHER® ELITE™ Sirolimus-Eluting Stent System, CYPHER® Bx VELOCITY® Sirolimus-eluting Stent System
- Where
- United States
- Volunteers
- 678 people
- Sponsor
- Cordis US Corp.
Coronary Artery Disease
The Nordic-Baltic Bifurcation Study IV
How should coronary artery stenoses with significant side branch be stented? A strategy of stenting both main vessel and side branch compared to a strategy of stenting the main vessel and only stenting the side branch if…
- Trial name
- BIF IV (NCT01496638)
- Testing
- Implantation of coronary stent in bifurcation lesion
- Where
- Denmark
- Volunteers
- 450 people
- Sponsor
- Evald Hoej Christiansen
Coronary Disease
Cobalt Chromium Stent With Antiproliferative for Restenosis II Trial (COSTAR II)
The purpose of this study is to evaluate the safety and effectiveness of the investigational stent CoStar™ Paclitaxel-Eluting Coronary Stent- a reservoir based DES system in comparison to a surface coated DES stent (TAXUS™…
- Trial name
- NCT00165035
- Testing
- CoStar Paclitaxel Drug Eluting Coronary Stent System, TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent
- Where
- 2 sites in United States
- Volunteers
- 1,701 people
- Sponsor
- Cordis US Corp.
Coronary Artery Disease
OCT- Versus Angiography-guided Paclitaxel Drug-Coated Balloon Angioplasty in De Novo Coronary Artery
OCT allows precise evaluation of intimal injury after lesion preparation and may improve the acute results and long-term outcomes after paclitaxel drug-coated balloon angioplasty.
- Trial name
- NCT04276389
- Testing
- OCT-guided paclitaxel drug-coated balloon angioplasty, Angiography-guided paclitaxel drug-coated balloon angioplasty
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Beijing Anzhen Hospital
Coronary Artery Disease
Elixir Medical Clinical Evaluation of the DESolve® Novolimus Eluting Bioresorbable Coronary Scaffold System - The DESolve Nx Trial
To evaluate the safety, performance and efficacy of the Elixir DESolve® Novolimus Eluting Bioresorbable Coronary Scaffold System (BCSS) in patients with a single de novo native coronary artery lesion designated the target lesion…
- Trial name
- NCT02086045
- Testing
- DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System
- Where
- 13 sites in Belgium, Brazil and 4 more
- Volunteers
- 126 people
- Sponsor
- Elixir Medical Corporation
Coronary Artery Disease
Effectiveness and Safety of Coronary Scoring Balloon Dilation Catheter in the Pretreatment of Coronary Stenosis Lesions
This trial adopts a prospective, multicenter, randomized controlled, and non-inferiority comparison trial design, and plans to recruit 200 eligible subjects who will be randomly assigned to the experimental group or the control…
- Trial name
- NCT06291545
- Testing
- Coronary artery scoring balloon dilation catheter（JW Medical Systems Ltd）, ScoreFlex NC Coronary Dilatation Catheter
- Volunteers
- 200 people
- Sponsor
- JW Medical Systems Ltd
Ischemic Heart Disease, Restenosis
Treatment of Bifurcation Lesions by SINGLE STENT and KISSing Balloon Trial
The use of DES have not diminished the need of improved treatment strategies , especially the treatment of bifurcation lesions still leave much to be clarified.
- Trial name
- SINGLEKISS (NCT00798954)
- Testing
- Sirolimus-eluting coronary stent (Cypher), Paclitaxel-eluting stent (TAXUS)
- Where
- 17 sites in Japan
- Volunteers
- 800 people
- Sponsor
- Vulnerable Plaque Society
Coronary Artery Disease
The CYPHER™ Stent Study in Patients With Small de Novo Coronary Artery Lesions.
The main objective of this study is to assess the effectiveness of the CYPHER™ (sirolimus-eluting) stent in reducing in-lesion late lumen loss in de novo native coronary artery lesions in small vessels (2.25 - 2.75 mm) as…
- Trial name
- SVELTE (NCT00235066)
- Testing
- PCI
- Where
- Switzerland
- Volunteers
- 100 people
- Sponsor
- Cordis US Corp.
Coronary Artery Disease
LONG-DES VI (Drug Eluting Stent for Long Lesions in Coronary Artery)
This is a multi-center, randomized, study to compare the efficacy of zotarolimus-eluting stent (Resolute Integrity or Resolute Onyx stent) or everolimus-eluting stent (Xience Prime or Xience Xpedition or Xience Alpine stent) for…
- Trial name
- NCT01489761
- Testing
- percutaneous coronary intervention
- Where
- 11 sites in South Korea
- Volunteers
- 302 people
- Sponsor
- Seung-Jung Park
Coronary Artery Disease
A Study of the Cypher SES to Treat Restenotic Native Coronary Artery Lesions.
The main objective of this study is to assess the safety and effectiveness of the Cypher™ sirolimus-eluting stent in reducing angiographic in-lesion late loss in patients with an in-stent restenotic native coronary artery lesion.
- Trial name
- TROPICAL (NCT00232856)
- Testing
- drug-eluting stent
- Where
- 2 sites in Belgium, Germany
- Volunteers
- 162 people
- Sponsor
- Cordis US Corp.
Coronary Artery Disease
NEXUS Study for the Treatment of de Novo Native Coronary Artery Lesions
The objective of this study is to evaluate the effectiveness and safety of the CYPHER NxT Sirolimus-eluting Coronary Stent on the BX SONIC Over-the-Wire (OTW) Stent Delivery System (SDS) in patients with de novo native coronary…
- Trial name
- NCT00231283
- Testing
- CYPHER NxT SES ON BX SONIC OTW STENT DELIVERY SYSTEM (SDS)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Cordis US Corp.
Arterial Occlusive Diseases, Myocardial Ischemia
RESOLUTE Japan SVS: The Clinical Evaluation of the MDT-4107 DES in the Treatment of De Novo Lesions in Small Diameter Native Coronary Arteries
The objective of the study is To verify the safety and efficacy of the MDT-4107 Drug-Eluting Coronary Stent in the treatment of de novo lesions in native coronary arteries with a reference vessel diameter (RVD) that allows the…
- Conditions
- Arterial Occlusive Diseases, Myocardial Ischemia, Cardiovascular Diseases, Coronary Artery Disease
- Trial name
- RJ-SVS (NCT01150500)
- Testing
- MDT-4107 Zotarolimus-Eluting Coronary Stent
- Where
- Japan
- Volunteers
- 65 people
- Sponsor
- Medtronic Vascular
Coronary Artery Disease
Elixir Medical Clinical Evaluation of the DESolve Myolimus Eluting Bioresorbable Coronary Stent System - DESolve I Trial
This prospective, consecutive enrolment, single-arm study will enroll up to 15 patients with single de novo, Type A lesions < 10 mm in length and located in a native coronary artery with a reference vessel diameter of 2.75 mm …
- Trial name
- NCT02086006
- Testing
- DESolve Novolimus Eluting Bioresorbable Coronary Scaffold
- Where
- 3 sites in Belgium, New Zealand
- Volunteers
- 16 people
- Sponsor
- Elixir Medical Corporation
Coronary Artery Disease
Cobra II Study: Use of the Cobra™ Cobalt Super Alloy Coronary Stent System in the Treatment of Coronary Artery Disease
To demonstrate the safety and efficacy of the Cobra Cobalt Super Alloy Balloon-Expandable Coronary Stent System for the treatment of de novo and restenotic (previously unstented) lesions in native coronary arteries in subjects…
- Trial name
- NCT00744107
- Testing
- PCI with the Cobra™ Cobalt Super Alloy Coronary Stent System
- Where
- 7 sites in Germany, Israel and 2 more
- Volunteers
- 258 people
- Sponsor
- Medlogics Device Corporation
Coronary Artery Disease, Left Main Coronary Artery Stenosis
Concordance Between FFR and iFR for the Assessment of Intermediate Lesions in the Left Main Coronary Artery. A Prospective Validation of a Default Value for iFR
The assessment of Left Main Coronary Artery (LMCA) lesions by means of coronary angiography renders serious limitations. Studies with a limited number of patients have shown that a value of FFR (Fractional Flow Reserve) above…
- Conditions
- Coronary Artery Disease, Left Main Coronary Artery Stenosis, Left Main Coronary Artery Disease, Restenosis, Coronary
- Trial name
- iLITRO (NCT03767621)
- Testing
- Indication of revascularization
- Where
- 38 sites in Spain
- Volunteers
- 300 people
- Sponsor
- Fundación EPIC
Coronary Artery Disease
Endeavor Zotarolimus - Eluting Stent in the Treatment Lesions in Small Native Coronary Arteries.
The objective of this study is to verify the safety and efficacy of the Endeavor Zotarolimus-Eluting Coronary Stent System for improving coronary luminal diameter in patients with ischemic heart disease due to de novo lesions of…
- Trial name
- ENDEAVORSVS (NCT00609947)
- Testing
- Endeavor Zotarolimus-Eluting Coronary Stent
- Where
- United States
- Volunteers
- 241 people
- Sponsor
- Medtronic Vascular